These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 15474715)
1. Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Whiting GC; Rijpkema S; Adams T; Corbel MJ Vaccine; 2004 Oct; 22(31-32):4245-51. PubMed ID: 15474715 [TBL] [Abstract][Full Text] [Related]
2. Identification of peptide sequences as a measure of Anthrax vaccine stability during storage. Whiting G; Wheeler JX; Rijpkema S Hum Vaccin Immunother; 2014; 10(6):1669-81. PubMed ID: 24637775 [TBL] [Abstract][Full Text] [Related]
3. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses. Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249 [TBL] [Abstract][Full Text] [Related]
4. 2-D reference map of Bacillus anthracis vaccine strain A16R proteins. Wang J; Ying T; Wang H; Shi Z; Li M; He K; Feng E; Wang J; Yuan J; Li T; Wei K; Su G; Zhu H; Zhang X; Huang P; Huang L Proteomics; 2005 Nov; 5(17):4488-95. PubMed ID: 16294314 [TBL] [Abstract][Full Text] [Related]
5. An immuno-diffusion assay to assess the protective antigen content of anthrax vaccine. Adams T; Osborn S; Rijpkema S Vaccine; 2005 Aug; 23(36):4517-20. PubMed ID: 15908061 [TBL] [Abstract][Full Text] [Related]
6. Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis. Ramirez DM; Leppla SH; Schneerson R; Shiloach J J Ind Microbiol Biotechnol; 2002 Apr; 28(4):232-8. PubMed ID: 11986925 [TBL] [Abstract][Full Text] [Related]
8. A study of the physiology of Bacillus anthracis Sterne during manufacture of the UK acellular anthrax vaccine. Charlton S; Herbert M; McGlashan J; King A; Jones P; West K; Roberts A; Silman N; Marks T; Hudson M; Hallis B J Appl Microbiol; 2007 Nov; 103(5):1453-60. PubMed ID: 17953556 [TBL] [Abstract][Full Text] [Related]
12. Rapid purification of recombinant anthrax-protective antigen under nondenaturing conditions. Ahuja N; Kumar P; Bhatnagar R Biochem Biophys Res Commun; 2001 Aug; 286(1):6-11. PubMed ID: 11485300 [TBL] [Abstract][Full Text] [Related]
13. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine. Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice. Sloat BR; Cui Z J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis. Rhie GE; Park YM; Han JS; Yu JY; Seong WK; Oh HB FEMS Immunol Med Microbiol; 2005 Aug; 45(2):341-7. PubMed ID: 16019195 [TBL] [Abstract][Full Text] [Related]
16. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens. Sloat BR; Shaker DS; Le UM; Cui Z FEMS Immunol Med Microbiol; 2008 Mar; 52(2):169-79. PubMed ID: 18194342 [TBL] [Abstract][Full Text] [Related]
17. Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid. Cui Z; Sloat BR Int J Pharm; 2006 Jul; 317(2):187-91. PubMed ID: 16730934 [TBL] [Abstract][Full Text] [Related]
18. Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. Ribot WJ; Powell BS; Ivins BE; Little SF; Johnson WM; Hoover TA; Norris SL; Adamovicz JJ; Friedlander AM; Andrews GP Vaccine; 2006 Apr; 24(17):3469-76. PubMed ID: 16519970 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a subunit vaccine against Bacillus anthracis. Chichester JA; Musiychuk K; de la Rosa P; Horsey A; Stevenson N; Ugulava N; Rabindran S; Palmer GA; Mett V; Yusibov V Vaccine; 2007 Apr; 25(16):3111-4. PubMed ID: 17280756 [TBL] [Abstract][Full Text] [Related]
20. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]